Protara Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative therapies for cancer and rare diseases. Its lead product, TARA-002, is a cell-based therapy in clinical trials for non-muscle invasive bladder cancer and lymphatic malformations. The company is also working on IV Choline Chloride, a phospholipid substrate aimed at patients requiring parenteral support. Protara prioritizes patient well-being and strives to address unmet medical needs through rigorous research and development. With a commitment to fostering a diverse and inclusive workplace, Protara offers a collaborative environment where employees can thrive while contributing to significant advancements in healthcare.